Press Releases March 30, 2026 08:00 PM

Manhattan Bridge Capital, Inc. Announces Payment of Quarterly Dividend

Manhattan Bridge Capital declares quarterly cash dividend to shareholders

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
LOAN

Manhattan Bridge Capital, Inc. announced a quarterly dividend of $0.11 per share, to be paid to shareholders of record on April 8, 2026, with the payment set for April 15, 2026, reflecting the company's commitment to returning value to its investors.

Manhattan Bridge Capital, Inc. Announces Payment of Quarterly Dividend
LOAN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Declared quarterly cash dividend of $0.11 per share.
  • Dividend record date set for April 8, 2026, with payment on April 15, 2026.
  • Demonstrates company’s ongoing shareholder value strategy and financial stability.

GREAT NECK, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) announced today that, in accordance with the board approved dividend declared on February 10, 2026, a cash dividend of $0.11 per share will be paid to all shareholders of record on April 8, 2026. The dividend will be paid on April 15, 2026.


Risks

  • Payment of dividends depends on sufficient earnings, which may fluctuate, impacting future dividend payments.
  • Economic conditions and interest rate changes could affect the company's lending business and dividend sustainability.
  • Market conditions may influence investor sentiment despite the dividend announcement, creating potential volatility.

More from Press Releases

GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders Jun 7, 2026 Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Jun 6, 2026 All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration Jun 6, 2026 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026